Eye Allergy Treatment Market Application And Share Analysis By Type (Vernal Keratoconjunctivitis, Atopic Keratoconjunctivitis, & Contact Allergic Conjunctivitis), Treatment (Medications & Allergy Shots), And End User (Hospitals & Clinics)-Forecast Till 2030

Eye Allergy Treatment Market Overview:

Global Eye Allergy Treatment Market Revenue, by Treatment, 2017 (USD Mn)

Sources: MRFR Analysis

Eye Allergy Treatment Market Segmentation

Global eye allergy treatment market has been segmented into type, treatment, and end user.

On the basis of type, it is segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, giant papillary conjunctivitis, and others. Vernal keratoconjunctivitis includes palpebral, limbal, corneal, and others.

On the basis of treatment, the eye allergy treatment market has been segmented into medication, allergy shots (immunotherapy), and others. Medication includes artificial tears, decongestants, oral antihistamines, antihistamine/mast-cell stabilizers, corticosteroids. Decongestants are further sub-segmented into with or without antihistamines. Allergy shots (immunotherapy) is sub-segmented into Subcutaneous Immunotherapy Treatment (SCIT) and Sublingual Immunotherapy Treatment (SLIT). The medication segment is projected to value 1860.78 million in 2023. Its larger market share is due to its effectiveness for the treatment of eye allergy. Moreover, with a lot of options available in the eye allergy treatment market, patients find medications much more acceptable in most cases. The wide acceptance of artificial tear as a first-line treatment option for eye allergy is driving the market.

On the basis of end user, it is segmented into eye hospitals & clinics, medical institutes, research centers, and others.

Global Eye Allergy Treatment Market Share, by Region, 2017 (%)

Sources: MRFR Analysis

Eye Allergy Treatment Market Regional Analysis

The Americas acquired the largest share of 40.4% is projected to grow at the highest CAGR during the forecast period. The growth of the Americas is due to its rising geriatric population and increasing ophthalmological disorders, causing an increased need for diagnosis and therapeutics. According to the National Eye Institute (NEI), about 3 million cases of conjunctivitis were reported in the US in 2015. This huge prevalence of eye allergies is driving the growth of the eye allergy treatment market.

Additionally, according to the US Census Bureau, in 2016, around 49.2 million residents were aged 65 and above in the US. This huge older population of the US contributed to over 15.2% of the total population which is likely to drive the market. Furthermore, the Americas is witnessing rampant advancements in technology. Thus, this increasing patient pool and increasing per capita income of citizens are going to propel the market growth of eye allergy treatments.

Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share owing to the rising patient population with eye disorders, availability of advanced treatment facilities, increasing healthcare expenditure, and the introduction of advanced therapies into the market along with the presence of good healthcare infrastructure. Additionally, rising government initiatives are driving the growth of the market. According to reports published by the United Kingdom Statistics Authority, in 2015, around 15,900 people were registered as visually impaired.

Asia-Pacific is the fastest-growing market for the global eye allergy treatment market. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the eye allergy treatment market in Asia-Pacific. Additionally, the rising elderly population is also fueling the market of eye allergy treatments in this region. According to the Asian Development Bank, Asia's elderly population is projected to reach nearly 923 million by 2050. This huge geriatric population is driving the growth of the market.

Eye Allergy Treatment Market Key Players

The prominent players in the global eye allergy treatment market are Allergan Plc, Johnson & Johnson Services Inc, Novartis AG, Bausch Health (Valeant Pharmaceuticals International Inc.), Santen Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries Ltd, Nicox, Akorn Inc., Shire, Nutra Essential OTC, and others.

Some of the key strategies followed by the players operating in the global eye allergy treatment market were innovation, product development, acquisition, and expansion.

• In 2017 the Novartis AG launched olopatadine hydrochloride ophthalmic solution, a generic version of Pataday eye drop. It is used in the treatment of allergic conjunctivitis. The firm has a presence across the world that enhances its market share.


• Santen Pharmaceutical Co. Ltd, in October 2018 launched Verkazia eye drops emulsion.


• Allergan Plc, in August 2016, acquired ForSight VISION5 Inc. (US). With this acquisition, the company aims to strengthen its eye care products portfolio and widen its geographic presence.

Eye Allergy Treatment Market Segmentation

Global Eye Allergy Treatment Market, by Type

• Seasonal and Perennial Allergic Conjunctivitis


• Vernal Keratoconjunctivitis


• Atopic Keratoconjunctivitis


• Contact Allergic Conjunctivitis


• Giant Papillary Conjunctivitis

Global Eye Allergy Treatment Market, by Treatment

• Medications
  
  
  
  • Artificial Tears
  
  
  • Decongestants
  
  
  • Antihistamine/Mast-Cell Stabilizers
  
  
  • Oral Antihistamines
  
  
  • Corticosteroids
  
  
  
  


• Allergy Shots (Immunotherapy)
  
  
  
  • Subcutaneous Immunotherapy Treatment (SCIT)
  
  
  • Sublingual Immunotherapy Treatment (SLIT)
  
  
  
  

Global Eye Allergy Treatment Market, by End User

• Hospitals and Clinics


• Specialty Centers

Global Eye Allergy Treatment Market, by Region

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • Russia
  
  
  • France
  
  
  • Italy
  
  
  • UK
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • India
  
  
  • Japan
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Latin America
  
  
  
  • Brazil
  
  
  • Mexico
  
  
  • Argentina
  
  
  • Rest of Latin America
  
  
  
  


• Middle East & Africa

Available Additional Customizations

• Company Profiles of Other Key Players


• Pfizer Inc. (US)


• Regeneron Pharmaceuticals, Inc. (US)


• Hoffmann-La Roche Ltd (Switzerland)


• Santen Pharmaceutical Co., Ltd (Japan)


• Valeant (Canada)

• End User Analysis (Example)

Intended Audience

• Eye allergy treatment medicines’ manufacturers


• Eye allergy treatment medicine and treatment providers


• Hospitals and clinics


• Medical Research Laboratories


• Research and Development (R&D) Companies


• Market Research and Consulting Service Providers


• Potential Investors

Report Scope:

Frequently Asked Questions (FAQ) :